Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1 by Cho, Tae-Joon et al.
The PDF of the article you requested follows this cover page. 
 
This is an enhanced PDF from The Journal of Bone and Joint Surgery
 2008;90:2735-2744.  doi:10.2106/JBJS.H.00014 J Bone Joint Surg Am.
Tae-Joon Cho, Joong-Bae Seo, Hye Ran Lee, Won Joon Yoo, Chin Youb Chung and In Ho Choi   
  
Pseudarthrosis of the Tibia Associated with Neurofibromatosis Type 1
Biologic Characteristics of Fibrous Hamartoma from Congenital
This information is current as of December 23, 2009 
 Reprints and Permissions
Permissions] link. 
 and click on the [Reprints andjbjs.orgarticle, or locate the article citation on 
 to use material from thisorder reprints or request permissionClick here to 
 Publisher Information
 www.jbjs.org
20 Pickering Street, Needham, MA 02492-3157
The Journal of Bone and Joint Surgery
Biologic Characteristics of Fibrous Hamartoma from
Congenital Pseudarthrosis of the Tibia Associated
with Neurofibromatosis Type 1
By Tae-Joon Cho, MD, Joong-Bae Seo, MD, Hye Ran Lee, MS, Won Joon Yoo, MD, Chin Youb Chung, MD, and In Ho Choi, MD
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Background: Fibrous hamartoma is a key pathologic component of congenital pseudarthrosis of the tibia, a challenging
and disabling bone disorder. We investigated the biologic characteristics of fibrous hamartoma cells in order to better
understand the pathogenesis of this rare disease.
Methods: Fibrous hamartoma tissues were surgically excised at the time of osteosynthesis from seven patients with
congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. Distal tibial periosteum was also
harvested as control tissue during tibial derotation osteotomy from two other patients with cerebral palsy and one patient
with idiopathic internal tibial torsion. Fibroblast-like cells were enzymatically dissociated and cultured from these tissues.
Immunophenotypes were investigated for positive (CD44 and CD105) and negative (CD45 and CD14) mesenchymal
lineage cell markers, and the mRNA expressions of bone morphogenetic protein(BMP)-2, BMP-4, and their receptors were
assayed by reverse transcription-polymerase chain reaction. After rhBMP-2 treatment, the changes in alkaline
phosphatase activity, and in the mRNA expressions of type-I collagen (COL1A1), alkaline phosphatase, and osteocalcin
genes, were assayed with use of an RNase protection assay. The mRNA expressions of receptor activator of nuclear factor-
kappa B ligand (RANKL) and osteoprotegerin (OPG) were quantitatively assayed with use of real-time RT-PCR. Osteoclastic
differentiation of RAW264.7 cells in coculture with fibrous hamartoma cells was evaluated.
Results: All fibrous hamartoma and tibial periosteal cells tested were CD441/CD1051/CD45–/CD14– and expressed
the mRNAs of BMP-2, BMP-4, and their receptors. The baseline mRNA expressions of COL1A1, alkaline phosphatase, and
osteocalcin genes in the fibrous hamartoma cells were diverse. These gene expressions were upregulated by BMP
treatment in tibial periosteal cells but did not change or were downregulated in fibrous hamartoma cells. Fibrous
hamartoma cells expressed higher levels of RANKL and lower levels of OPG than did tibial periosteal cells. Coculture with
fibrous hamartoma cells enhanced osteoclastic differentiation of RAW264.7 cells.
Conclusions: Fibrous hamartoma cells maintain some of the mesenchymal lineage cell phenotypes, but do not undergo
osteoblastic differentiation in response to BMP. They are more osteoclastogenic than are tibial periosteal cells.
Clinical Relevance: The low osteogenicity and high osteoclastogenicity of fibrous hamartoma cells may play a role in the
pathogenesis of congenital pseudarthrosis of the tibia. This should be taken into consideration when developing a
treatment protocol for congenital pseudarthrosis of the tibia.
C
ongenital pseudarthrosis of the tibia usually presents
as a congenitally dysplastic tibia with anterolateral
bowing, cystic lesion, sclerotic change, and/or di-
aphyseal narrowing, which fractures spontaneously or after
minor trauma and then establishes a pseudarthrosis if treated
conservatively1. Although surgical intervention has achieved
substantial improvements in terms of the healing rates of
congenital pseudarthrosis of the tibia over recent decades,
challenging problems still jeopardize the function of the af-
fected limb2.
Disclosure: In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in
excess of $10,000 from Seoul National University Hospital (SNUH-04-2007-039 and SNUH-04-2007-081). Neither they nor a member of their im-
mediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial
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Fibrous hamartoma is fibromatosis-like tissue at the
pseudarthrosis site, which is continuous with abnormally
thickened periosteum in adjacent bone segments, and has long
been regarded as the key pathology of congenital pseudar-
throsis of the tibia 3. An ultrastructural study found that the
vast majority of cells in fibrous hamartoma were fibroblasts
lacking a basement membrane in the stationary phase4. A more
recent histochemical and immunohistochemical study re-
vealed that fibrous hamartoma was composed of an undif-
ferentiated type of membranous tissue having the potential to
differentiate into several lines of mesenchymally derived tis-
sues5. On the other hand, impaired blood circulation by the
constricting fibrous hamartoma6 or by the accumulation of
nerve cells surrounding small arteries7 was also suggested as a
pathogenic mechanism of congenital pseudarthrosis of the
tibia. However, the cells composing fibrous hamartoma have
not been fully characterized in terms of osteogenicity and os-
teoclastogenic potential.
Congenital pseudarthrosis of the tibia is frequently as-
sociated with neurofibromatosis type 1 (NF1), which in patients
with congenital pseudarthrosis of the tibia has been reported to
have a prevalence ranging from 40% to 80%6, although only 1%
to 4% of patients with neurofibromatosis type 1 have con-
genital pseudarthrosis of the tibia develop8. Neurofibromatosis
Fig. 1-A
Fig. 1-B
Figs. 1-A, 1-B, and 1-C Flow cytometric analysis of tibial periosteum (TP) and fibrous hamartoma (FH) cells. Fig. 1-A Histograms representing the
number of cells (y axis) against the fluorescence intensity (x axis, log scale). Gates were set on 97% of the antibody-unlabeled data. Fig. 1-B
Proportions of cells positive for the surface markers. Tibial periosteal and fibrous hamartoma cells tested were positive for CD44 and CD105
and were negative for CD45 and CD14.
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type 1 is caused by mutation in the Nf1 gene, which encodes
neurofibromin9. As it converts active Ras-GTP into inactive
Ras-GDP, neurofibromin negatively regulates Ras activity10.
Nf1 is expressed in many types of cells, including maturing
chondrocytes, hypertrophic chondrocytes, osteoblasts, osteo-
cytes, and osteoclasts11. Furthermore, its expression has been
reported at fracture sites in a mouse model and at pseudar-
throsis sites in a rat model12, suggesting the involvement of
mutant Nf1 in the development of pseudarthrosis.
Loss of neurofibromin function and the subsequent
deregulation of Ras-MAPK activity may impair osteoblast
differentiation. Alkaline phosphatase staining and mRNA ex-
pressions of osteocalcin and osteonectin are decreased in mes-
enchymal stem cell-progenitor cells from Nf1± mice, which could











Label Age (yr) Sex Diagnosis Tissue FACS ALP Activity RPA
FH1 6.9 M CPT with NF1 Fibrous hamartoma X X X X X
FH2 3.7 F CPT with NF1 Fibrous hamartoma X X X X X
FH3 4.0 F CPT with NF1 Fibrous hamartoma X X X X X X
FH4 3.8 F CPT with NF1 Fibrous hamartoma X X X X X
FH5 9.2 M CPT with NF1 Fibrous hamartoma X X X X
FH6 4.3 F CPT with NF1 Fibrous hamartoma X
FH7 6.9 F CPT with NF1 Fibrous hamartoma X X
TP1 6.7 M Cerebral palsy Tibial periosteum X X X X
TP2 8.0 F Cerebral palsy Tibial periosteum X X X
TP3 11.2 F ITT Tibial periosteum X X
*FH = fibrous hamartoma, TP = tibial periosteum, CPT = congenital pseudarthrosis of the tibia, NF1 = neurofibromatosis type 1, ALP = alkaline
phosphatase, RPA = RNase protection assay, FACS = fluorescence-activated cell sorting, RANKL = receptor activator of nuclear factor-kappa B
ligand, OPG = osteoprotegerin, and ITT = idiopathic internal tibial torsion.
Fig. 1-C
Mean fluorescent intensities of the surface markers. All cells tested showed stronger intensity for
CD44 than CD105 but were negligible for CD45 and CD14.
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be restored by the reexpression of the NF1 functional domain13.
Moreover, the committed osteoprogenitors from Nf1± mice
exhibited premature apoptosis and higher proliferation, as well
as less osteoblastic differentiation14. Increased osteoclastic activity
has been well described at cortical bone surfaces in contact with
fibrous hamartoma3, and this may be another mechanism of the
development and recurrence of pseudarthrosis. Nf1 haploinsuf-
ficiency was found to sensitize osteoclast precursor cells, activate
osteoclasts, and help them to survive15,16.
In the current study, we investigated the biologic be-
havior of fibrous hamartoma cells, the key constituent of
congenital pseudarthrosis of the tibia, in order to better un-
derstand the pathogenesis of congenital pseudarthrosis of the
tibia, addressing the following questions: (1) What is the
phenotype of fibrous hamartoma cells? (2) Do fibrous ham-
artoma cells differentiate into osteoblasts in response to bone
morphogenetic protein signaling? (3) Do fibrous hamartoma




This study was approved by the institutional review board ofSeoul National University Hospital. Human tissues were
harvested and used in experiments with informed consent.
Fibrous hamartoma tissue was harvested from seven patients
Fig. 2
Figs. 2-A and 2-B Effect of rhBMP-2 treatment on the mRNA expression of COL1A1, alkaline phosphatase (ALP), and
osteocalcin (OC) genes. Fig. 2-A An RNase protection assay was performed to compare BMP-treated and nontreated
cells. Fig. 2-B Band intensities were normalized against that of L32 (a ribosomal protein used as a ‘‘housekeeping’’
gene). BMP treatment upregulated the expressions of these mRNAs in tibial periosteal (TP) cells, whereas it did not
change or even downregulated in fibrous hamartoma (FH) cells.
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with an atrophic type of congenital pseudarthrosis of the tibia
associated with NF1, during surgical procedures of osteosyn-
thesis. Distal tibial periosteum was harvested during supra-
malleolar tibial derotation osteotomy as a normal control from
two patients with spastic diplegic cerebral palsy and one pa-
tient with idiopathic internal tibial torsion. Fibroblast-like cells
were enzymatically dissociated from these tissues and were
plated on a 100-mm dish and cultured in Dulbecco’s modified
Eagle medium (DMEM) containing 10% fetal bovine serum
and antibiotics at 37C in 5% CO2. When the second passage
cells reached confluence, they were trypsinized, frozen, and
stored in liquid nitrogen until required. The cells from each
patient were denoted by the labels listed in Table I as FH1
through FH7 and TP1 through TP3. As the amount of tissue
harvested from the patients was limited, not all tissues were
used in all experiments (Table I).
Fluorescence-Activated Cell Sorting Analysis
Immunophenotypes of fibrous hamartoma and tibial periosteal
cells were analyzed by fluorescence-activated cell sorting (FACS).
CD44 (matrix receptor) and CD105 (transforming growth factor-
a [TGF-a] coreceptor) were used as positive mesenchymal lin-
eage cell markers, and CD45 and CD14 (hematopoietic lineage
markers) were used as negative markers17,18. Cells (5 · 105) from
each specimen were incubated with rat anti-human CD44 mono-
clonal antibody (eBioscience, San Diego, California) and mouse
anti-human CD45 antibody (DakoCytomation, Glostrup, Den-
mark). Another 5 · 105 cells from each specimen were incu-
Fig. 3
Figs. 3-A and 3-B Effect of rhBMP-2 on alkaline phosphatase (ALP) activity. Fig. 3-A BMP treatment increased
alkaline phosphatase activity in TP1 (tibial periosteal) cells, but decreased it in all fibrous hamartoma (FH) cells
tested. The error bars indicate the standard deviation. *The difference between nontreated and BMP-treated cells
was significant (p < 0.05). **p < 0.01 (Mann-Whitney test). p-NP = p-nitrophenol. Fig. 3-B Data are presented as
percentage changes of alkaline phosphatase activity in BMP-treated cells compared with nontreated cells.
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bated with mouse anti-human CD105 antibody (AbD Serotec,
Raleigh, North Carolina) and mouse anti-human CD14 anti-
body (DakoCytomation). Cells incubated with human immu-
noglobulin G1 (IgG1) were used as negative controls. Cells
were analyzed with use of a FACStar flow cytometer (for at
least 10,000 events) and CellQuest software (both products
were from Becton Dickinson, Oxford, United Kingdom).
RNA Assays
Total RNA was extracted from plated cells with use of a Trizol
reagent (Invitrogen, Carlsbad, California). The mRNA expres-
sions of two bone morphogenetic proteins (BMP-2 and BMP-4)
and bone morphogenetic protein receptor types 1A, 1B, and 2
(BMPR1A, BMPR1B, and BMPR2) were assayed by reverse
transcription-polymerase chain reaction (RT-PCR), in order to
investigate whether these cells have endogenous osteoblastogenic
signals and receptors for them. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control.
The mRNA levels of receptor activator of nuclear factor-
kappa B ligand (RANKL) and osteoprotegerin (OPG) were
quantitatively analyzed by real-time RT-PCR. After reverse
transcription with use of the SuperScript First-Strand Syn-
thesis System for RT-PCR (Invitrogen), real-time PCR was
performed in TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, California) with use of an ABI Prism
7000 Sequence Detection System (Applied Biosystems). To
compare the different gene expression levels, threshold cycle
values were compared for relative gene expression analysis. All
samples were amplified three times, and mean values were
used in calculations. The expression levels of target genes were
presented as a ratio of the gene expression to GAPDH mRNA
expression.
Human genes encoding COL1A1 (type-I collagen), al-
kaline phosphatase, and osteocalcin were subcloned from the
RT-PCR product with use of the pGEM-T Easy Vector System
(Promega, Madison, Wisconsin). An RNase protection assay
Fig. 4-A
Fig. 4-B
The estimated mRNA levels of RANKL (receptor activator of nuclear factor-kappa B ligand) (Fig.
4-A) and OPG (osteoprotegerin) (Fig. 4-B) in tibial periosteal (TP) and fibrous hamartoma (FH)
cells as determined by quantitative real-time RT-PCR. The mRNA level was estimated from the
threshold cycle value and was standardized by that of GAPDH. The mean value in tibial peri-
osteal cells was set at 1.0 in this graph. Fibrous hamartoma cells showed higher RANKL mRNA
levels and lower OPG mRNA levels than did tibial periosteal cells.
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was performed as previously described19. Total RNA was ex-
tracted from the cells grown in osteogenic media (DMEM
containing 10% fetal bovine serum, 100 nM dexamethasone,
10 mM sodium glycerophosphate, and 0.05 mM ascorbic acid-
2-phosphate) with 0 or 100 ng/mL rhBMP-2 (R and D Sys-
tems, Minneapolis, Minnesota) for two weeks. 32P-labeled
cRNA probes were generated, with use of RNA transcription
kits (Pharmingen, San Diego, California), hybridized with 10
mg of total RNA, and then digested with RNase with use of
RiboQuant ribonuclease protection kits (Pharmingen). Pro-
tected segments of cRNA probes were fractionated by dena-
turing polyacrylamide gel electrophoresis (PAGE). Specific
bands formed by each cRNA probe were quantified and nor-
malized against L32 (a ‘‘housekeeping’’ gene).
Fig. 5
Figs. 5-A and 5-B Differentiation of RAW264.7 cells into osteoclast-like cells by coculture with fibrous hamartoma (FH) cells.
Fig. 5-A Coculture with TP2 and TP3 (tibial periosteal) cells produced less osteoclast-like cells. Cocultures with fibrous
hamartoma cells produced many TRAP (tartrate-resistant acid phosphatase)-positive, multinuclear cells (·200). Fig. 5-B The
numbers of osteoclast-like cells formed during coculture with fibrous hamartoma cells were significantly higher than those
with tibial periosteal (TP) cells (p < 0.01, Mann-Whitney test). RANKL = receptor activator of nuclear factor-kappa B ligand.
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Alkaline Phosphatase Activity Assays
Cells were plated at 3 · 104 cells per well into twenty-four-well
plates and were grown in osteogenic media with 0 or 100 ng/mL
rhBMP-2 (R and D Systems) for two weeks. Alkaline phos-
phatase activities were chemically determined as previously
described20. Ratios of the alkaline phosphatase activities of
BMP-treated and nontreated cells were calculated.
RAW264.7 Coculture Study
Cells from the RAW264.7 cell line (ATCC [American Type
Culture Collection], Rockville, Maryland), a murine monocyte-
macrophage cell line known to differentiate into osteoclast-like
cells after RANKL stimulation21, were plated at 1 · 103 cells per
well into a ninety-six-well plate along with tibial periosteal or
fibrous hamartoma cells at 1 · 103 cells per well, and cultured
in a-MEM containing 8% fetal bovine serum for five days.
Then they were fixed with 1% paraformaldehyde, and tartrate-
resistant acid phosphatase (TRAP) histochemical staining was
performed. TRAP-positive multinuclear cells with more than
two nuclei were counted.
Results
Fibrous Hamartoma Cells Maintained Mesenchymal
Lineage Phenotype
Spindle-shaped adherent cells were enzymatically dissoci-ated from fibrous hamartomas of patients with congenital
pseudarthrosis of the tibia and from the distal tibial perios-
teum of patients with cerebral palsy. Fibrous hamartoma cells
could not be differentiated from tibial periosteal cells on the
basis of morphology. Cells from one tibial periosteal specimen
and six fibrous hamartoma specimens were tested for im-
munophenotype. All of the cells expressed CD44 and CD105
but were negative for CD45 and CD14 (Figs. 1-A, 1-B, and
1-C). The mRNA expressions of BMP-2 and BMP-4 and of
their receptors were examined in cells from one tibial perios-
teal specimen and five fibrous hamartoma specimens by RT-
PCR. Although the assay was not quantitative, all of the cells
tested strongly expressed the mRNAs of BMPs and their
receptors. With regard to COL1A1, alkaline phosphatase, and
osteocalcin mRNA expression, RNase protection assay showed
that the tibial periosteal cells expressed the mRNAs of all of the
three osteoblastic marker genes even without BMP treatment.
COL1A1 and alkaline phosphatase mRNA were detected with-
out BMP treatment in all of the fibrous hamartoma cells tested,
but osteocalcin mRNA expression was detected only in cells
from two fibrous hamartoma specimens (FH2 and FH3) (Figs.
2-A and 2-B) (Table I). These findings indicate that fibrous
hamartoma cells maintained some mesenchymal lineage phe-
notype but were at different stages of osteoblastic differentiation.
BMP Treatment Did Not Enhance the Osteoblastic
Differentiation of Fibrous Hamartoma Cells
The finding that all tissues expressed the mRNAs of BMPs and
of their receptors led us to investigate the response to exoge-
nous BMP. Tibial periosteal cells showed a 4.9-fold increase in
alkaline phosphatase activity after two weeks of rhBMP-2
treatment. However, in all fibrous hamartoma cells tested, al-
kaline phosphatase activity reduced after rhBMP-2 treatment.
The alkaline phosphatase activities of BMP-treated fibrous
hamartoma cells ranged from 1.1% to 71.7% of those not
treated with BMP (Figs. 3-A and 3-B).
BMP markedly increased the mRNA expressions of
COL1A1, alkaline phosphatase, and osteocalcin in tibial peri-
osteal cells, but showed a variable effect in fibrous hamartoma
cells. BMP induced no change in these mRNA expressions in
FH2 and FH4 cells (Table I). On the other hand, FH1 and FH3
cells (Table I) showed a marked decrease in the mRNA ex-
pressions of COL1A1 and alkaline phosphatase. FH3 cells,
which expressed osteocalcin mRNA without BMP treatment,
did not produce any detectable osteocalcin mRNA band after
treatment with rhBMP-2 (Figs. 2-A and 2-B).
Fibrous Hamartoma Cells Are Strongly Osteoclastogenic
RANKL is a cytokine that promotes osteoclast differentiation
when it binds to RANK, while OPG is a soluble decoy receptor
that binds to RANKL, thereby inhibiting the effect of RANKL
on osteoblasts and osteoclast precursors. The relative levels of
RANKL and OPG mRNAs compared with that of GAPDH
were estimated in cells from three tibial periosteal and four
fibrous hamartoma specimens. The RANKL/GAPDH mRNA
ratio was higher in cells from the four fibrous hamartoma
specimens than in cells from the three tibial periosteal speci-
mens. When the mean value of the three tibial periosteal
specimens was set at 1.0 (range, 0.44 to 1.66), the values of the
four fibrous hamartoma specimens ranged from 2.47 to 118.8,
with an average of 48.1. On the other hand, the OPG/GAPDH
mRNA ratio was lower in fibrous hamartoma cells than in
tibial periosteal cells. When the mean value of the three tibial
periosteal specimens was set at 1.0 (range, 0.32 to 1.66), the
values of the four fibrous hamartoma specimens ranged from
0.091 to 0.20, with an average of 0.15 (Figs. 4-A and 4-B).
We also tested the osteoclastogenic activity of fibrous
hamartoma cells in a RAW264.7 cell coculture experiment.
When 1 · 103 RAW264.7 cells were cocultured with 1 · 103 cells
from two tibial periosteal specimens, a mean (and standard
deviation) of only 5.2 ± 0.84 (TP2) or 9.5 ± 1.9 (TP3) TRAP-
positive, multinucleated cells was formed (Table I). However,
when RAW264.7 cells were cocultured with cells from fibrous
hamartoma specimens, the mean numbers of TRAP-positive,
multinucleated cells per well were 34.4 ± 26.0, 45.6 ± 12.0,
57.2 ± 24.7, and 110.8 ± 13.9, respectively, revealing significantly
higher osteoclastogenic activity than that with tibial periosteal
cells (p < 0.01, Mann-Whitney test) (Figs. 5-A and 5-B).
Discussion
Fibrous hamartoma is a fibromatosis-like lesion found atpseudarthrosis sites, and is a key component of the pa-
thology of congenital pseudarthrosis of the tibia1,3, which is
believed to originate from aberrant periosteum growth. In the
current study, we characterized the fibrous hamartoma cell
phenotype, and found it to be CD441/CD1051/CD45–/
CD14–, which is consistent with the immunophenotype of
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mesenchymal lineage cells17,18. This immunophenotype was
shared by tibial periosteal cells, which were presumed to rep-
resent normal control of fibrous hamartoma tissue. This study
also showed expression of BMPs and their receptors in fibrous
hamartoma cells. The diverse expression pattern of later stage
osteoblastic marker genes in fibrous hamartoma cells treated
with exogenous BMP (Figs. 2-A and 2-B) suggests that fibrous
hamartoma tissue may be composed of cells of mesenchymal
lineage at different stages of osteoblastic differentiation from
case to case.
It is interesting to note that all tibial periosteal and fi-
brous hamartoma cells tested expressed the mRNAs of BMP-2,
BMP-4, and of their receptors, indicating autocrine or para-
crine BMP signals. However, the response of fibrous hamar-
toma cells to exogenous rhBMP-2 treatment was different
from that of tibial periosteal cells. In all of the fibrous ham-
artoma cells tested, alkaline phosphatase activity was reduced
by rhBMP-2. Moreover, rhBMP-2 did not change or even
downregulated the mRNA expressions of osteoblastic marker
genes in fibrous hamartoma cells. These findings suggest that
fibrous hamartoma cells are arrested at a certain stage during
osteoblastic differentiation. As endogenous BMPs and their
receptors express in fibrous hamartoma cells, aberrant re-
sponses to BMP signaling may be due to perturbation of the
intracellular signaling transduction pathway. All patients in-
volved in the present study had the NF1 phenotype, which is
caused by a heterozygous mutation in the Nf1 gene encoding
neurofibromin9. Nf1 haploinsufficient mice showed a lower
number of mesenchymally originated cells with the osteoblastic
phenotype13 and premature apoptosis, higher proliferation,
and attenuated differentiation of committed osteoprogeni-
tors14. Moreover, Schindeler et al. showed reduced efficacy
of surgically implanted rhBMP-222. Therefore, the Nf1 ±
genotype could contribute to fibrous hamartoma develop-
ment by blocking the osteoblastic differentiation of periosteal
cells.
Because BMP has produced promising results in animal
bone-healing models, and has proven clinical efficacy for the
treatment of adult tibial nonunion and spinal fusion, several
authors have investigated the effects of BMP in congenital
pseudarthrosis of the tibia. However, the reported results are
contradictory. In two case reports, successful osteosynthesis
was achieved23,24, but in a case series of five patients with
congenital pseudarthrosis of the tibia who were treated with
rhBMP-7 and intramedullary rods or external fixation, un-
equivocal union was achieved only in one patient25. The in vitro
data obtained during the present study suggest that BMP
treatment may not induce fibrous hamartoma cells to differ-
entiate to osteoblasts. Rather, BMP signaling may impair os-
teoblastic differentiation of fibrous hamartoma. However,
exogenous BMP might affect the healthy osteoblastic lineage
cells to differentiate into osteoblasts, contributing to healing of
the pseudarthrosis.
Increased osteoclastic activity appears to be essential in
the development and recurrence of pseudarthrosis. Several
studies have been conducted on the effect of Ras signaling on
osteoclastogenesis15,16. Inhibiting Ras by dominant negative
Ras overexpression rapidly induced the apoptosis of osteo-
clasts, whereas ERK activation by constitutively active MEK1
increased their survival15. Moreover, the inhibition of ERK
phosphorylation by PD98059 (a MAPK/ERK kinase-1 inhibi-
tor) caused a loss of ruffled border, apoptosis, and a loss of
polarity in osteoclasts16. These findings support that Nf1
haploinsufficiency and subsequent Ras-MAPK overactivity in
osteoclasts and their precursors should enhance osteoclasto-
genesis. The current study provides evidence that fibrous
hamartoma cells positively affect osteoclasts and their pre-
cursors; the RANKL-to-OPG ratio was much higher in fibrous
hamartoma cells than in distal tibial periosteal cells, and co-
culture with fibrous hamartoma cells significantly enhanced
the osteoclastic differentiation of RAW264.7 cells. Therefore, in
patients with neurofibromatosis type 1, fibrous hamartoma
tissue appears to further activate osteoclasts and their precur-
sors, which were already activated by Nf1 haploinsufficiency.
These findings suggest that inhibition of osteoclastic
activity may be effective in the management of congenital
pseudarthrosis of the tibia. Schindeler et al.22 showed that the
addition of bisphosphonate improved deficient ectopic bone
formation by BMP-2 in Nf1± mice. The suppression of osteo-
clasts is also expected to prevent fibrous hamartoma tissue
from encroaching into tibial bone tissue and thus help osteo-
synthesis or prevent recurrence of fracture. However, little is
known of the long-term safety of bisphosphonate in patients
young enough to be growing, and thus the benefits and risks
of this type of therapeutic intervention require careful
investigation.
There are several limitations in this study. First, because
of the rarity of congenital pseudarthrosis of the tibia and the
difficulty in obtaining normal periosteum, the numbers of
both control subjects and patients with congenital pseudar-
throsis of the tibia were too small to allow statistical analysis
and to draw any solid conclusion. Second, cells from primary
tissue culture may not represent all of the cellular populations
in fibrous hamartoma. Third, as these results are from in vitro
experiments performed in environments totally different from
that in the human body, the cells are not necessarily expected
to behave as in experiments in vivo. Fourth, as specimens used
in this study were harvested from patients with an established,
atrophic type of congenital pseudarthrosis of the tibia associ-
ated with neurofibromatosis type 1 in a certain age range,
fibrous hamartoma from other types of congenital pseudar-
throsis of the tibia not associated with neurofibromatosis type
1 or in another age group may behave differently. Also, the
current study cannot explain why congenital pseudarthrosis of
the tibia develops preferably at the distal ends of the tibia and
fibula. Despite these limitations, this study revealed that fi-
brous hamartoma in congenital pseudarthrosis of the tibia
associated with neurofibromatosis type 1 consists of cells that
maintain some mesenchymal lineage cell phenotypes, and the
low osteogenicity and high osteoclastogenicity of these fibrous
hamartoma cells can be the key pathogenic mechanism of
congenital pseudarthrosis of the tibia. These findings need to
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be taken into consideration when planning the treatment of
patients with congenital pseudarthrosis of the tibia. n
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